CD206-targeted glucocorticoid 101-PGC-005 beat dexamethasone in 309-patient Phase 2/3 trial (HR 2.31); steroid-sparing data at ACR Poster 0122, Nov 8 ...
The first College Football Playoff rankings come out two weeks from today. Kentucky continues to be included in projections after the 6-1 start.
Resonance Consulting, founded by education researcher Dr. Johanna Groene, has begun implementing its Human-AI Stewardship ...
The strongest evidence for staying steady on your feet comes from a handful of moves most people can do by the kitchen counter.
Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF) ("Devonian" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative botanical therapeutics targeting ...
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in ...
Rapport Therapeutics’ RAP-219 met its primary endpoint in acute bipolar mania with a 3.1-point placebo-adjusted improvement ...
EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with annualized htTKV growth as the primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results